Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rosiglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 15/20 | 1.00 |
| ▸ | RXRA | P19793 | 2/20 | 0.87 |
| ▸ | RARG | P13631 | 1/20 | 0.87 |
| ▸ | PPARA | Q07869 | 2/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rosiglitazone SCHEMBL5169 | 1.00 | PPARG (1.00) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL2355017 | 1.00 | PPARG (1.00) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL29530259 | 1.00 | PPARG (1.00) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL7052472 | 1.00 | PPARG (1.00) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL3375739 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL3377103 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL5468691 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL6976956 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL1489117 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL3381790 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581052-A1 | COMPOSITIONS AND METHODS FOR DIRECTING APOLIPOPROTEIN L1 TO INDUCE MAMMALIAN CELL DEATH | University of Georgia Research Foundation, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| WO-2024182425-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES/DISORDERS | NOUREDDINE ACHRAF (US) | 2024-09-06 | — | — | WO | disclosed |
| EP-4412614-A1 | COMPOSITIONS AND METHODS FOR ENHANCING WNT SIGNALING FOR TREATING CANCER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-08-14 | — | — | EP | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| CN-117897155-A | Use of PPARgamma agonists or MPC inhibitors for the treatment of primary, congenital diseases of the heart muscle (cardiomyopathy) | 预防治疗有限公司 | 2024-04-16 | — | — | CN | disclosed |
| WO-2024050524-A1 | COMPOSITIONS AND METHODS FOR DIRECTING APOLIPOPROTEIN L1 TO INDUCE MAMMALIAN CELL DEATH | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| EP-4313038-A1 | USE OF PPAR-GAMMA AGONISTS OR MPC INHIBITORS FOR TREATING PRIMARY, INNATE DISEASES OF THE CARDIAC MUSCLE (CARDIOMYOPATHIES) | Preventage Therapeutics GmbH (DE) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023060226-A1 | COMPOSITIONS AND METHODS FOR ENHANCING WNT SIGNALING FOR TREATING CANCER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-04-13 | — | — | WO | disclosed |
| CN-109803687-B | Antibody-mediated autocatalytic targeted delivery of nanocarriers to tumors | 耶鲁大学 | 2022-11-15 | — | — | CN | disclosed |
| US-8815837-B2 | Respiratory disease treatment | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2014-08-26 | — | — | US | disclosed |
| US-20120264787-A1 | Respiratory Disease Treatment | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2012-10-18 | — | — | US | disclosed |
| US-20120264787-A1 | Respiratory Disease Treatment | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2012-10-18 | — | — | US | disclosed |
| US-8236786-B2 | Respiratory disease treatment | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2012-08-07 | — | — | US | disclosed |
| US-8236786-B2 | Respiratory disease treatment | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2012-08-07 | — | — | US | disclosed |
| US-20110053986-A1 | RESPIRATORY DISEASE TREATMENT | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20110053986-A1 | RESPIRATORY DISEASE TREATMENT | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010015818-A1 | RESPIRATORY DISEASE TREATMENT | ARGENTA DISCOVERY LIMITED (GB) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | PPARG, PPARA, PPARD | PPARG 1/4885RXRA 12/4885RARG 15/4885 |
| US-20120264787-A1 | Respiratory Disease Treatment | IL5, PPARD, PPARG | PPARG 3/4885RXRA 191/4885RARG 90/4885 |
| US-20110053986-A1 | RESPIRATORY DISEASE TREATMENT | IL5, PPARD, PPARG | PPARG 3/4885RXRA 191/4885RARG 90/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | PPARG 495/4885RXRA 143/4885RARG 293/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | PPARG 288/4885RXRA 242/4885RARG 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.